Semax

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the ACTH(4-10) fragment of adrenocorticotropic hormone, with a Pro-Gly-Pro tail added for enzymatic stability. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, it is approved in Russia as an intranasal nootropic and neuroprotective agent. Crucially, it retains ACTH's cognitive and neurotrophic effects while lacking its adrenal cortisol-stimulating activity.

It rapidly upregulates BDNF and NGF in the hippocampus and cortex (within 30 minutes intranasally), modulates dopamine and serotonin, inhibits enkephalinase, and binds melanocortin receptors. Clinically this translates to improved focus, working memory, verbal fluency, motivation, stress tolerance, and neuroprotection. Its best-documented use is acute ischemic stroke recovery; for healthy users, cognitive gains are real but modest (roughly 10-20%).

Start with 100-200 mcg intranasally in the morning for the first week to assess tolerability, then move to a standard 300 mcg morning dose by week 2. If response is insufficient after 2-4 weeks, increase to 600 mcg, with total daily exposure typically 300-900 mcg divided morning and early afternoon. Standard 0.1% solution delivers 50 mcg per spray. Do not dose after 2-3 PM (sleep disruption), and cycle in 2-8 week courses with 1-2 week breaks.

Acute effects begin 15-30 minutes after intranasal dosing, peak at 30-60 minutes, and last 4-8 hours. Because the plasma half-life is only 2-3 minutes, the sustained effects come from BDNF/NGF gene expression changes. Chronic benefits accumulate over 2-8 weeks of regular use, creating a new cognitive baseline — this combination of fast onset plus chronic accumulation distinguishes it from both stimulants and SSRIs.

No. It is approved in Russia for stroke recovery, cognitive disorders, and optic nerve atrophy and is on Russia's Vital & Essential Drugs List, but it has never been submitted for FDA or EMA approval (largely a commercial decision, since it is off-patent). It was removed from the FDA's Category 2 bulk substances list in April 2026 and is scheduled for PCAC review in July 2026; that review concerns potential 503A compounding status, not drug approval. In the US it circulates as an unscheduled research chemical.

Semax has an excellent safety profile. The most common effects are mild nasal irritation, transient headache with first doses, mild initial dizziness, and — if dosed too late — sleep disruption. No dependence, tolerance, withdrawal, cardiovascular effects, or emotional blunting have been reported over 20+ years of Russian clinical use. Avoid in pregnancy, lactation, active psychosis, and untreated bipolar mania.

Selank (also from the same Russian lab) is primarily anxiolytic — calm and stress tolerance — while Semax is primarily nootropic — sharper focus, alertness, and drive; combined they give 'calm focus.' N-Acetyl Semax Amidate is a modified analog with N-terminal acetylation and C-terminal amidation that extend its half-life and bioavailability; it is a different, longer-acting molecule, and some vendors mislabel one as the other, so mass-spec identity confirmation is important.

Some people with ADHD-like presentations find it useful as a non-stimulant alternative or adjunct, and Russian practice includes it for 'minimal brain dysfunction' in children; its dopaminergic and BDNF effects are mechanistically relevant, but the effect is more modest than stimulants and ADHD warrants proper medical evaluation. It can be combined with stimulants like modafinil but requires caution, since both enhance dopaminergic signaling and the combination can cause over-activation.